CAR-T cell manufacturing: Major process parameters and next-generation strategies

Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoim...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The Journal of experimental medicine Ročník 221; číslo 2
Hlavní autoři: Ayala Ceja, Melanie, Khericha, Mobina, Harris, Caitlin M, Puig-Saus, Cristina, Chen, Yvonne Y
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 05.02.2024
Témata:
Autoimmune Diseases
Humans
Immunotherapy, Adoptive
T-Lymphocytes
ISSN:1540-9538, 1540-9538
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1540-9538
1540-9538
DOI:10.1084/jem.20230903